

References



ภาษาไทย

นิพนธ์ พวงวินทร์. โรคลมชัก. คลินิก. 6 (กุมภาพันธ์ 2533): 87-96.

ภาษาอังกฤษ

Alldredge, K.B. Seizure disorder. In T. Herfindal, D.Gourley and L. L.Heart(eds.),

Clinical Pharmacy and Therapeutics, (5th ed.), U.S.A.: Willium & Wilkins, 1992.

Anlezark, G., Horton, R.W., Weldrum, B.S. and Sawaya, M.C.B. Anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate and the metabolism of γ -aminobutyric acid (GABA) in mice with audiogenic seizure. Biochem. Pharmacol. 25(1976): 413.

Biggs, C.S., Pearce, B.R., Fowler, L.J., and Whitton, P.S. The effect of sodium valproate on extracellular GABA and other amino acid in the rat ventral hippocampus: an in vivo microdialysis study. Brain Res. 594(1992): 138-142.

Benveniste, H., and Huttemeier, P.C. Microdialysis-theory and Application. Prog. Neurobio. 35 (1990): 195-215.

Bialer, M, Haj-Yehia, A., Badir, K., and Hadad, S. Can we develop improved derivatives of valproic acid? Pharmacy World & Science. 16(1994): 2-5.

Blaise, F.D., and Bourgeois, M.D. Pharmacologic interactions between valproate and other drugs. Am. J. Med. 84 (Suppl 1A) (1988): 29-33.

- Browning, R.A. Overview of neurotransmission: Relationship to the action of antiepileptic drugs. In C.L. Faingold and G.H. Fromn (eds.), Drugs for control of epilepsy, pp. 23-56. Florida: CRC Press, 1991.
- Burnham, W.M. Antiseizure drugs (anticonvulsants). In R. Kalant (ed.), Principles of medical pharmacology, (5th ed.), pp. 203-213. Singapore: B.C. Decker Inc., 1989.
- Chatchai Powthongchin. Anticonvulsant activity of (2'-propylpentanoyl)-2-pyrolidinone and its effects on γ -aminobutyric acid (GABA) levels in rat cerebral cortex. Master's Thesis, Chulalongkorn University, 1994.
- Collins, R., and Ferrendelli, J.A. Neurochemistry of epileptic discharge. In, S.G. Eleasson, A.L. Prensky, and W.B. Hardin, Jr. (eds.), Neurological pathophysiology, pp.196-198. New York: Oxford University, 1978.
- Cooper, J.R. Bloom, F.E., and Roth, R.H. The biochemical basis of neuropharmacology, (6 th ed.), 133-189. New York: Oxford University Press, 1991.
- Davies, J., and Richens, A. Neuropharmacology. In, J. Laidlaw, A. Richens and D.Chadwick, Textbook of epilepsy, (4th ed.), pp. 1-19. London: Churchill Livingstone, 1993.
- Davidoff, R.A. Studies of neurotransmitter action (GABA, glycine and convulsants). In, A.A. Ward, J.K. Penry, and D.P. Purpura (eds.) Epilepsy: Association for research in nervous and mental disease, Vol 61, pp. 53-85. New York: Raven Press, 1983.
- Davis, R., Peters, D.H., and McTavish, D. Valproic acid: A Reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47 (1994): 332-372.

- De Deyn, P.P., and Macdonald, R.L. Effects of antiepileptic drugs on GABA responses and on reduction of GABA responses by PTZ and DMCM on mouse neurons in cell culture. Epilepsia. 30(1989): 17-25.
- Diem, K. and Lentner, C. Scientific tables. (7 th ed.), pp. 54-55. Germany : Ciba-Geigy Limited; 1972.
- Dreifuss, F.E., et al. Valproic acid hepatic fatalities: A retrospective review. Neurology. 37 (1987): 379-385.
- Dunham, N.W. and Miya, T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46(1957): 208-209.
- Eadie, M.J., McKinnon, G.E., Dunstan, P.R., MacLaughlin, D, and Dickinson, R.G. Valproate metabolism during hepatotoxicity associated with the drug. Quart. J. Med. 284(1990): 1229-1240.
- Faden, A.L., Ellison, J.A., and Noble, L.J. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur. J. Pharmacol. 175(1990): 165-174.
- Ferrendelli, J.A., Holland, K.D., McKeon, A.C., and Covey, D.F. Comparison of the anticonvulsant activities of Ethosuximide, Valproate, and a new anticonvulsant, Thiobutyrolactone. Epilepsia. 30(1989): 617-633.
- File, S.E., and Aranko, Kari. Sodium valproate decreases exploratory behaviour in mice: development of tolerance and cross-tolerance with chlordiazepoxide. Eur. J. Pharmacol. 151(1988): 293-299.
- Fukuzako, H., and Izumi, K. Clinical aspects of the epilepsies. In, G. Tunnicliff and B.U. Raess, (eds.), GABA mechanisms in epilepsy, pp. 1-30. New York: Wiley-Liss, 1991.

- Furlanut, M., Schiaulini, P., and Rizzoni, G. Possible enzymatic inhibition by valproate. Int. Clin. Pharm. Res. 11(1982): 269-272.
- Geddes, J.W., and Wood, J.D. Changes in amino acid content of nerve endings (synaptosomes) induced by drugs that alter the metabolism of glutamate and γ -Aminobutyric acid. J. Neurochem. 42(1984): 16-24.
- Goldensohn, E.S., Glaser, G.H., and Goldberg, M.A. Epilepsy. In, L.P. Rowland (ed.), Merritt's textbook of neurology, (7 th ed.), pp. 629-632. Philadelphia: Lea&Febiger, 1984.
- Goldring, S. Pathophysiology of epileptic discharge. In, S.G.Eleasson, A. L. Prensky, and W.B. Hardin, Jr. (eds.), Neurological pathophysiology , pp. 183-195. New York: Oxford University, 1978.
- Godin, Y., Heiner, L., Merk, J., and Mandal, P. Effects of di-n-propylacetate, an anticonvulsant compound, on GABA metabolism. J. Neurochem. 19 (1969): 869-873.
- Hardin, W.B.Jr. Pathophysiology of clinical epilepsy. In, S.G. Eleasson, A.L. Prensky, and W.B. Hardin, Jr.(eds.), Neurological pathophysiology, pp. 173-178. New York: Oxford University, 1978.
- Hopkin, A. Clinical neurology, pp. 186-207. New York: Oxford University Press, 1993.
- Horton, R.W. GABA dysfunction in animal models of epilepsy. In, G. Tunnicliff, and B.U. Raess (eds.), GABA mechanisms in epilepsy, pp.121-147. New York: Wiley-Liss, 1991.
- Iadarola, M.J., and Gale, K. Dissociation between drug-induced increase in nerve terminal and non-nerve terminal pools of GABA in vivo. Eur. J. Pharmacol. 59(1979): 125-129.

- Johnston, D. Valproic acid: update on its mechanisms of action. In, R. H. Levy (ed.), Valproate modern perspectives, Vol.25 (Suppl.1), pp. 51-54. Washington: Revan Press, 1984.
- Kuriyama, K., Hirouchi, M. and Nakayasu. Structure and function of cerebral GABA_A and GABA_B receptors. Neurosci. Res. 17(1993): 91-99.
- Lindroth, P., and Mopper, K. High performance liquid chromatographic determination of subpicomole derivatization of amino acids by precolumn fluorescence derivatization o-phthalodialdehyde. Anal. Chem. 51(1979): 1667-1674.
- Litchfield, J.T., and Wilcoxon, F.W. A simplified method of evaluating dose-effect experiments. J Pharmacol. Exp. Ther. 96(1949): 99-119.
- Lloyd, K.G., Munari, C., Bossi, L., Stoeffels, C., Talairach, J., and Morselli, P.L. Biochemical evidence for the alterations of GABA-mediated synaptic transmission in pathological brain tissue (Stereo EEG or Morphological definition from epileptic patients). In, P.L. Moselli, K.G. Lloyd, W. Loscher B. Meldrum and E.H. Reynolds.(eds.). Neurotransmitters, seizures, and epilepsy, pp. 325-334. New York: Raven Press, 1981.
- Loscher, W. Pharmacological, toxicological and neurochemical effects of D2(E)-valproate in animals. Pharm. Week. Sci. 14(3A)(1992); 139-143.
- _____.et al. The role of technical ,biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs.III. Pentylenetetrazole seizure models. Epilepsy Res. 8(1991); 174- 189.
- _____.and Nolting, B. The role of technical, biological and pharmacological factors in the laboratory evaluation anticonvulsant drugs.IV. Protective indices. Epilepsy Res. 9(1991): 1-10.

- Nolting, B., and Fassbender, C. The role if technical, biological and pharmacological fctors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles. Epilepsy Res. 7(1990) : 173-181.
- and Vetter, M. In vivo effects of aminoxyacetic acid and valproic acid on nerve terminal(synaptosomal) GABA levels in discrete brain areas of the rat. Biochem. Pharmacol. 34(1985): 1747-1756.
- Macdonald ,R.L. Antiepileptic drug actions. Epilepsia. 30(Suppl.1) (1989): s19-s28.
- MacGeer, P.L., Eccle, J.C., and McGeer, E.G. Molecular neurobiology of the mammalian brain, (2 nd. ed.), pp.175-234. New York: Plenum Press, 1988.
- McLean, M.J., and Macdonald, R.L. Sodium valproate, but not ethosuximide, produce use and voltage dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharm. Exp. Ther. 237(1986): 1001-1011.
- Menkes, J.H. Textbook of child neurology, (4th ed.), pp 602-674. Philadelphia: Lea & Febiger, 1990.
- Moore, M., et al. Valproate: recent findings and perspective. Epilepsia. 25 (Suppl.1) (1984): s5-s9.
- Neal. M.J. Medical Pharmacology at a glance, pp.46-53. London: Blackwell, 1987.
- Pellegrino, J.L., Pellegrino, A.S., and Crushman, A.J. A stereotaxic atlas of the Rat Brain. New York: Plenum Pressation, 1979.
- Penry, J.K., Valproic acid. Am.J.Med. 84 (Suppl 3) (1988): 1-2.
- and Dean, J.C. The scope and use of valproate in epilepsy. J.Clin. Psychiatry. 50(Suppl 3) (1993): 17-22.

- Phillips, N.I., and Fowler, L.J. The effects of sodium valproate on γ -aminobutyrate metabolism and behaviour in naive and ethanolamine-o-sulphate pretreated rats and mice. Biochem. Pharmacol. 31(1982): 2257-2261.
- Pinder, R.M., Brogden, R.N., Speight, T.M. and Avery, G.S. A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 13 (1977): 81-123.
- Porter, R.J. Classification of epileptic seizures and epileptic syndromes. In, J. Laidlaw, A. Richens and D. Chadwick, Textbook of epilepsy, (4 th ed.), pp.1-19. London: Churchill Livingstone, 1993.
- Rall, T.W., and Schleifer, L.S. Drugs effective in the therapy of the epilepsies. In, A.G. Gilman (ed.), Goodman and Gilman's the pharmacological basic of therapeutics, (5th ed.), pp. 436- 462. New York: Pergamon Press, 1990.
- Richens, A. and Perucca, E. Clinical pharmacology and medical treatment. In, J. Laidlaw, A. Richens and D. Chadwick. Textbook of epilepsy, (4th ed.), pp.1-19. London: Churchill Livingstone, 1993.
- Rogawski, M.A., and Porter , R.J. Antiepileptic drugs: Pharmacological mechanism and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42(1990): 223-286.
- Schmidt, D. Adverse effects of antiepileptic drugs, pp. 145-148. New York: Revan Press, 1982.
- Simler, S., Ciesielski, L., Maitre, M., Randrianarisoa. H., and Mandel, P. Effect of sodium n-dipropylacetate on audiogenic seizures and brain GABA level. Biochem. Pharmacol. 22(1973): 1701-1708.

- Snead, O.C. The gamma hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models, Epilepsia. 29(1988), 361-366.
- Swinyard, E.A., and Woodhead, J.H. Experimental detection, quantification and evaluation of anticonvulsants. In, D.M. Woodbury, J.K. Penry and C.E. Pippenger (eds.), Antiepileptic Drugs, pp. 111-126. New York: Revan Press, 1982.
- Thompson, E.B. Drug Bioscreening: Drug evaluation in pharmacology., pp 1-15. New York: VCH Publisher, 1990.
- Thoungchai Sooksawate. Anticonvulsant effects of N-(2-propylpentanoyl)urea. Master's Thesis, Chulalongkorn University, 1995.
- Ticku, M.K., and Rastogi, R.K. Convulsant/ Anticonvulsant drugs and GABAergic transmission. In G, Nistico, P.L. Morselli, K.G. Lloyd and J. Engel (eds.) Neurotransmitters, seizures and epilepsy III, pp. 163-176. New York: Raven Press, 1986.
- Tunnicliff, G and Raess, . GABA amino acid transferase inhibitors as potential antiepileptic agents, In, G.Tunnicliff, and B.U. Raess (eds.), GABA mechanisms in epilepsy, pp. 189-204. New York: Wiley-Liss, 1991.
- , and Raess, B.U. GABA neurotransmitter activity in human epileptogenic brain. In G.Tunnicliff and B.U.Raess(eds.), GABA mechanisms in epilepsy, pp. 105-119. New York: Wiley-Liss, 1991.
- Whitton, P.S., and Fowler, L. J. The effect of valproic acid on 5-hydroxy indoleacetic acid concentration in hippocampal dialysates in vivo. Eur. J. Pharm. 200 (1991): 167-169.

- Wilder, B.J., and Rangel, R.J. Review of valproate monotherapy in the treatment of generalized tonic-clonic seizures. Am. J. Med. 84 (Suppl 1A) (1988): 7-12.
- Zaccara, G., Messori, A., and Moroni, F. Clinical pharmacokinetics of valproic acid. Clin-Pharmacokinet. 15(1988): 367-89.
- Zeise, M.L., Lasparow, S., Zieglgansberger, W. Valproate suppresses N-methyl-D-aspartate evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544(1991): 345-348.
- Zona, C., and Avoli, M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp. Brain. Res. 81(1990): 313-317.

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

Appendixs



Horizontal count within 75 min after the injection 15 min

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	32	1122.03	836.83	147.93
PEG400*	32	410.53	855.41	151.22
VPA100*	32	561.03	1003.36	177.37
VPA200*	32	316.56	478.84	84.65
HMV35*	32	228.09	272.96	48.25
HMV75*	32	406.13	644.94	114.01

* p < 0.01 statistically significant from NSS

Sleeping time

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	8	59.00	13.01	4.59
PEG400	8	85.13	22.84	8.07
VPA100 ^{a,c}	9	108.70	27.28	8.63
VPA200 ^{a,b}	8	141.43	45.15	17.07
HMV35 ^{c,d}	10	84.20	36.23	11.46
HMV75 ^{a,b}	9	128.89	23.56	7.85

^a
p < 0.01 statistically significant from NSS

^b
p < 0.01 statistically significant from PEG

^c
p < 0.01 statistically significant from VPA200

^d
p < 0.05 statistically significant from HMV75

Total amount of GABA within 180 min after injection

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	36	61.77	26.63	4.86
PEG400	42	75.86	26.26	4.05
VPA200 ^a	41	103.41	44.83	7.00
VPA400 ^a	42	114.27	45.03	6.94
HMV75 ^{b,c}	45	79.35	33.67	5.69
HMV150 ^{a,c}	45	95.69	18.60	3.58

^a p < 0.05 statistically significant from NSS and PEG400

^b p < 0.05 statistically significant from VPA200

^c p < 0.05 statistically significant from VPA400

Amount of GABA at various time

Time 1 (20 min after injection)

Group	count	Mean	Standard Deviation	Standard Error
NSS	4	77.51	4.37	2.19
PEG400	5	81.73	14.84	6.63
VPA200	5	95.75	17.58	7.86
VPA400	4	99.26	20.15	10.07
HMV75	5	74.79	30.41	15.20
HMV150	5	94.75	21.81	12.59

Time 2 (40 min after injection)

Group	count	Mean	Standard Deviation	Standard Error
NSS	4	84.38	15.41	8.89
PEG400	5	76.65	23.21	10.28
VPA200	5	94.79	44.13	19.74
VPA400	5	103.28	18.67	8.35
HMV75	5	76.36	25.05	12.53
HMV150	5	96.22	13.40	7.73

Time 3 (60 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	83.24	28.35	14.16
PEG400	5	85.93	32.25	14.42
VPA200	5	90.33	17.45	7.80
VPA400	5	118.07	18.69	8.36
HMV75	5	78.40	45.18	22.59
HMV150	5	87.27	16.24	9.38

Time 4 (80 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	56.62	19.39	11.19
PEG400	5	75.65	20.34	9.09
VPA200 ^a	5	108.18	33.49	14.98
VPA400 ^a	5	113.00	35.78	16.00
HMV75 ^{b,c}	5	64.47	20.90	10.45
HMV150	5	101.54	23.32	13.46

^a p < 0.05 statistically significant from NSS

^b p < 0.05 statistically significant from VPA200

^c p < 0.05 statistically significant from VPA400

Time 5 (100 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	58.25	33.82	16.91
PEG400	5	75.02	17.13	7.66
VPA200 ^a	4	122.06	61.97	27.72
VPA400 ^a	4	134.47	83.83	41.92
HMV75 ^b	5	69.24	26.79	13.39
HMV150	5	100.33	20.37	11.76

^a p < 0.05 statistically significant from NSS

^b p < 0.05 statistically significant from VPA400

Time 6 (120 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	47.16	30.79	17.78
PEG400	5	74.21	8.37	11.74
VPA200	5	97.08	43.61	19.50
VPA400 ^a	4	113.41	41.55	20.77
HMV75	5	79.46	34.01	17.01
HMV150	5	89.78	12.26	7.08

^a p < 0.05 statistically significant from NSS

Time 7 (140 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	60.58	12.78	7.38
PEG400	4	73.39	25.23	12.61
VPA200	4	92.63	48.50	24.25
VPA400	4	111.59	43.00	19.23
HMV75	5	96.38	60.51	30.25
HMV150	5	84.82	13.04	7.53

Time 8 (160 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	37.72	24.18	12.09
PEG400	4	53.57	43.88	21.94
VPA200	4	103.01	71.22	35.61
VPA400	5	122.92	85.77	38.36
HMV75	5	76.33	32.82	16.41
HMV150	5	112.27	34.76	20.08

Time 9 (180 min after injection)

Group	count	Mean	Standard Deviation	Standard Error of Mean
NSS	4	40.03	32.51	22.99
PEG400	4	83.07	49.53	24.76
VPA200	4	138.73	79.56	45.93
VPA400	5	113.31	42.63	19.06
HMV75	5	105.21	31.58	18.24
HMV150	5	94.24	15.94	9.20

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

Curriculum vitae



Miss pornchulee Supatchaipisit was born on 25 th November, 1969, in Songklha, Thailand. She had graduated with Bachelor Degree in Nursing of Science from Faculty of Medicine Ramathibodi Hospital, Mahidol University in 1991. After graduation, she was experienced in nurse at Clinical research ward, Ramathibodi Hospital, for two years.

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย